Email this article Serological and molecular genetic markers of hepatitis C virus in infected donors
- Issue: Vol 55, No 5 (2010)
- Pages: 34-36
- Section: Articles
- Submitted: 09.06.2023
- Published: 15.10.2010
- URL: https://virusjour.crie.ru/jour/article/view/12049
- ID: 12049
Cite item
Full Text
Abstract
The frequency of hepatitis C virus (HCV) markers was determined in donors; the spectrum and activity of specific antibodies (anti-HCV), the distribution of virus genotypes, and HCV RNA concentrations were studied in virus carrier donors. The activity of antibodies in HCV RNA-negative donors was significantly lower than that in HCV RNA-positive donors (p ≤ 0.001). There was a statistically significant difference in antibody activities in donors infected with genotype 1b as compared with those infected with genotype 3a (p ≤ 0.001). However, no correlation was found between the concentration of a virus genome and the activity of specific antibodies.
The risk for obtaining infected blood donations was determined during plasma screening by enzyme immunoassay (EIA). Our investigations have indicated that the frequency of serological window period donations is one case per 74750 test plasma units and that of HCV RNA-positive donations with low antibody positivity coefficients, which are frequently detectable as seronegative during screening for laboratory errors, is one case per 37375 test units. A combination of EIA and polymerase chain reaction has shown to minimize the risk of contamination of donor plasma with HCV markers.
The risk for obtaining infected blood donations was determined during plasma screening by enzyme immunoassay (EIA). Our investigations have indicated that the frequency of serological window period donations is one case per 74750 test plasma units and that of HCV RNA-positive donations with low antibody positivity coefficients, which are frequently detectable as seronegative during screening for laboratory errors, is one case per 37375 test units. A combination of EIA and polymerase chain reaction has shown to minimize the risk of contamination of donor plasma with HCV markers.
References
- Гаранжа Т. А., Туполева Т. А., Гуляева А. А. и др. Типоспецифические антитела к вирусу гепатита C в сыворотках больных с различными заболеваниями крови // Журн. микробиол. - 2001. - № 2. - С. 72-76.
- Гланц С. Медико-биологическая статистика: Пер. с англ. - М., 1998.
- Масалова О. В., Самохвалов Е. И., Петракова Н. В. и др. Выявление маркеров вируса гепатита C - белка нуклеокапсида, РНК и вирусспецифических антител в плазмах крови доноров // Вопр. вирусол. - 2000. - № 2. - С. 14-18.
- Миронов К. О., Гущин А. Е., Шипулина О. Ю., Шипулин Г. А. Разработка и клиническая апробация тест-системы "Амплисенс HCV-1/2/3" // Сборник трудов 6-й Всероссийской науч.-практ. конф. "Молекулярная диагностика-2007". - М., 2007. - Т. 1. - С. 260-265.
- Guide to the preparation, use and quality assurance of blood components. Recommendation N R (95) 15. - 12-th ed. Council of Europe, 2006.
- Hitzler W. E., Runkel S. Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV // Transfusion. - 2001. - Vol. 41, N 3. - P. 333-337.
- Offergeld R., Ritter S., Hamouda O. HIV, HCV, HBV and syphilis infections among blood donors in Germany 2005. Report from the Robert Koch Institute in accordance with Article 22 of the Transfusion Act/Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. - 2007. - Vol. 50, N 10. - P. 1221-1231.
- Stramer S. L., Glynn S. A., Kleinman S. N. et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing // N. Engl. J. Med. - 2004. - Vol. 351, N 8. - P. 760-768.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).